We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$1.65M
Cap. Flow
+$718
Cap. Flow %
0%
Top 10 Hldgs %
60.41%
Holding
141
New
23
Increased
22
Reduced
12
Closed
32

Top Buys

Rank Stock Value
1
INMB icon
INmune Bio
INMB
+$5.31M
2
STAA icon
STAAR Surgical
STAA
+$5.12M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$2.44M
4
NVNO
enVVeno Medical
NVNO
+$1.94M
5
CVX icon
Chevron
CVX
+$1.6M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.85M
2
U icon
Unity
U
+$3.33M
3
SKIN icon
SkinHealth Systems
SKIN
+$2.9M
4
FFIV icon
F5
FFIV
+$2.71M
5
NVAX icon
Novavax
NVAX
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 78.61%
2 Financials 5.86%
3 Technology 3.93%
4 Communication Services 3.41%
5 Consumer Discretionary 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGTC
101
DELISTED
Applied Genetic Technologies Corporation
AGTC
$60K 0.03%
20,000
– –
TMDX icon
102
Transmedics
TMDX
$2.64B
$33K 0.02%
1,000
– –
AVGR
103
DELISTED
Avinger, Inc. Common Stock
AVGR
$26K 0.01%
117
– –
TECX
104
Tectonic Therapeutic
TECX
$558M
$17K 0.01%
250
– –
ALDX icon
105
Aldeyra Therapeutics
ALDX
$96.5M
$13K 0.01%
1,500
– –
PHXM
106
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$12K 0.01%
200
– –
GNCA
107
DELISTED
Genocea Biosciences, Inc.
GNCA
$10K 0.01%
5,000
– –
ABNB icon
108
Airbnb
ABNB
$90.5B
$8K ﹤0.01%
50
– –
AI icon
109
C3.ai
AI
$1.54B
– –
-80
Closed -$1K
ANVS icon
110
Annovis Bio
ANVS
$79.6M
– –
-12,000
Closed -$1.03M
ARQT icon
111
Arcutis Biotherapeutics
ARQT
$3.39B
– –
-12,000
Closed -$328K
AXSM icon
112
Axsome Therapeutics
AXSM
$11B
– –
-13,500
Closed -$911K
BNGO icon
113
Bionano Genomics
BNGO
$12.3M
– –
-58
Closed -$257K
BTU icon
114
Peabody Energy
BTU
$2.78B
– –
-20,000
Closed -$159K
CKPT
115
DELISTED
Checkpoint Therapeutics
CKPT
– –
-20,500
Closed -$605K
EZGO
116
EZGO Technologies
EZGO
$2.15M
– –
0
– -$5K
FBRX icon
117
Forte Biosciences
FBRX
$1.57B
– –
-643
Closed -$541K
FFIV icon
118
F5
FFIV
$23.4B
– –
-14,500
Closed -$2.71M
INMD icon
119
InMode
INMD
$874M
– –
-45,200
Closed -$2.14M
KC
120
Kingsoft Cloud Holdings
KC
$3.75B
– –
-4,500
Closed -$153K
KZIA
121
Kazia Therapeutics
KZIA
$137M
– –
-500
Closed -$247K
MRNA icon
122
Moderna
MRNA
$22.5B
– –
-4,500
Closed -$1.06M
NVAX icon
123
Novavax
NVAX
$1.27B
– –
-10,300
Closed -$2.19M
NVDA icon
124
NVIDIA
NVDA
$5.31T
– –
-36,000
Closed -$721K
HTT
125
High Templar Tech Ltd
HTT
$398M
– –
-25,000
Closed -$61K
2 3 4
5
6

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, ACT Capital Management held 141 positions worth $193M, down 0.85% from $195M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

ACT Capital Management's Q3 2021 filing shows 23 new, 22 increased, 12 reduced and 32 closed positions. Its largest new stake was INmune Bio: 275,000 shares worth $5.34M. The largest sale was Filana Therapeutics, an estimated $3.85M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials and Technology.

  • ACT Capital Management's largest Q3 2021 buy was INmune Bio: 275,000 shares worth $5.34M.
  • ACT Capital Management added most to STAAR Surgical in Q3 2021, an estimated $5.12M increase.
  • ACT Capital Management's biggest Q3 2021 reduction was Unity, cutting an estimated $3.33M.
  • ACT Capital Management fully exited Filana Therapeutics in Q3 2021, selling an estimated $3.85M.
  • ACT Capital Management's ten largest holdings make up 60% of its $193M portfolio in Q3 2021.
  • ACT Capital Management opened 23 new positions and closed 32 in Q3 2021.
  • ACT Capital Management's portfolio value fell 0.85% quarter-over-quarter to $193M.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.